Alert icon

To align with industry best practices for security and data integrity, Project Data Sphere is requiring users to upgrade their browsers to one that supports encryption protocol TLS 1.2 by December 15, 2017. On that date, Project Data Sphere will disable support of browsers that permit SSL 3.0/TLS 1.0. To prevent any disruption to your access to Project Data Sphere, you must take action.
This browser was not recognized and may not be compatible with TLS 1.2 or higher. Please check with the browser's developer to confirm.
To view information about this, please visit the FAQ. If you have any further questions, please contact us.

Alert icon

This dataset is available to Authorized Users of the Project Data Sphere Cancer Research Platform through an initiative with the National Cancer Institute (NCI) of the U.S. National Institutes of Health (NIH). To gain access to this dataset, you must complete the following steps:

  1. Add the dataset to your request by clicking 'Add to Request' button below. You may add dataset(s) with up to 5 clinical trials in a single request.
  2. After adding all desired datasets to your request, you must complete a request form accessible via the 'My Data Requests' link in your account profile. After submitting your data request form, your request will be delivered to NCI for approval.
  3. Once your request is approved, you will receive notice that you have access to the dataset(s) in SAS® Life Sciences Analytic Framework within the Project Data Sphere Cancer Research Platform and that you may download the dataset(s) onto a personal machine.

To be able to request access to this data and the other analytic tools click here.

NCT00118209

Phase III Randomized Study of R-CHOP V. Dose-Adjusted EPOCH-R With Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas

Unique Dataset IDnci-data-432ClinicalTrial.gov IDNCT00118209
DownloadableNo
SponsorAlliance for Clinical Trials in OncologyData ProviderNational Cancer InstituteTotal Study Enrolled Patients0RandomizationN/APubMed (PMID)30939090.0
Study PhaseN/ABlinding MethodN/AType(s) of dataN/AIntervention TypeN/ADataset TypeN/A

Clinical Trial Title

Phase III Randomized Study of R-CHOP V. Dose-Adjusted EPOCH-R With Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas

Trial Summary and Conditions

N/A

Data Summary

N/A

Study Objectives

N/A

Outcome Measures

Primary: Progression-Free Survival Rate at 2 and 5 Years [ Time Frame: Up to 5 years post-registration ]. Secondary: Response Rate [ Time Frame: Up to 5 years post-registration ] The overall response rate is defined as the percentage of participants with a response (Complete Response or Partial Response); Overall Survival Rate at 2 and 5 Years [ Time Frame: Up to 5 years post-registration ] Overall survival is defined as the time from randomization to death due to any cause. Other: Whether the Gene Expression Signatures That Were Previously Associated With Survival Following CHOP Therapy Are Associated With Survival in Either of the Treatment Arms of the Prospective Trial [ Time Frame: Up to 5 years post-registration ]

ClinicalTrial.gov

Below are the clinical trial(s) associated with this dataset (all links are to ClinicalTrials.Gov):

NCI Description

Dataset NCT00118209-D1-Dataset.csv (master) is one of 2 datasets (NCT00118209-D1 and NCT00118209-D2) associated with PubMed ID 30939090. This dataset contains information that will allow you to reproduce the baseline characteristics table, primary and secondary analyses, and the primary cause of death.

Available Downloads: NCT00118209-D1

To gain access to the data and analytic tools click here.

Data Dictionary: NCT00118209-D1-Data-Dictionary_3.pdf

DATA: NCT00118209-D1-Dataset_3.csv

OTHER: README.pdf

Available Downloads: NCT00118209-D2

To gain access to the data and analytic tools click here.

Data Dictionary: NCT00118209-D2-Data-Dictionary_3.pdf

DATA: NCT00118209-D2-Dataset_3.csv

OTHER: README.pdf